Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab (neoHIP)

NCT03747120 is registered in ClinicalTrials.gov with University of Texas Southwestern Medical Center as lead sponsor.

NCT NCT03747120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03747120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab (neoHIP)
Lead sponsor
University of Texas Southwestern Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 25, 2019
Completion date
December 31, 2029
Enrollment
138 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2-positive breast cancer